SCHEMBL26529105

SCHEMBL26529105

Cc1ccc(Cn2nc(-c3cnc(OCC(C)(F)F)nc3)ccc2=O)cn1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 8/20 0.40
▸ MEN1 O00255 5/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ MAPT P10636 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ POLB P06746 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ PDE4A P27815 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ CHEK1 O14757 1/20 0.37
▸ NEK2 P51955 1/20 0.37
▸ LIMK1 P53667 1/20 0.37
▸ TYRO3 Q06418 1/20 0.37
▸ CLK4 Q9HAZ1 1/20 0.37
▸ GRIN1 Q05586 1/20 0.37
▸ GRIN2B Q13224 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29569742 0.93 MEN1 (0.41) METMEN1KMT2AMAPTTP53
SCHEMBL23558978 0.93 MEN1 (0.41) METMEN1KMT2AMAPTTP53
SCHEMBL26529054 0.87 MET (0.46) METMEN1KMT2APDE4APDE4B
SCHEMBL26529033 0.86 MAPT (0.38) METMEN1KMT2AMAPTTP53
SCHEMBL26530932 0.84 MET (0.43) METMEN1KMT2AMAPTTP53
SCHEMBL26529073 0.84 MEN1 (0.35) METMEN1KMT2AMAPTTP53
SCHEMBL26999000 0.82 MAPT (0.39) METMEN1KMT2AMAPTTP53
SCHEMBL26999063 0.82 MET (0.52) METMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL29569490 0.82 MET (0.43) METMEN1KMT2ATP53PDE4A
SCHEMBL23528280 0.82 MET (0.43) METMEN1KMT2ATP53PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, MUSK, SMN1; SMN2 MET 4319/4885MEN1 4467/4885KMT2A 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback